Thank you for Subscribing to Life Science Review Weekly Brief
×
Life Science Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review
Taking Cell Isolation and Spray Technology to Next Level
Life Sciences Review | Wednesday, October 27, 2021
The innovative product’s growing patent portfolio opens up new commercial options in fields such as cell treatments, biologics, drug delivery, and other sectors, allowing for smart business partnerships with potential partners.
FREMONT, CA:Today, developing and commercializing next-generation biomedical technology and devices to solve unmet medical needs is the need of the hour. To take their progressions a step ahead, RenovaCare, a developer of patented cell therapy technologies for the regeneration of skin and tissues, has designed a SkinGun. The RenovaCare SkinGun is a non-invasive mild cell spray that aids in the healing of burn wounds. The product was also recently awarded a patent by the United States Patent and Trademark Office.
The latest RenovaCare patent underscores the company’s dedication to new product development and the expansion of its patented cell isolation and spray technology platforms to cover biologics and drug delivery. Further, SkinGun’s growing patent portfolio opens up new commercial options in fields such as cell treatments, biologics, drug delivery, and other sectors, allowing for smart business partnerships with potential partners.
RenovaCare has had several technological advancements recently and growth of its intellectual property portfolio, with new patents awarded in the United States, Australia, Canada, and many European and Asian countries. “RenovaCare has adopted a global IP strategy focused on investing in technology and broadening our commercial opportunities domestically and abroad,” stated Dr. Kaiyo Nedd, CEO and President, RenovaCare. “A stronger patent portfolio better secures our technology from third-party appropriation and infringement while enhancing the value of our corporate assets.”
In May 2021, the FDA granted RenovaCare full Investigational Device Exemption, allowing the company to begin a clinical trial to assess the safety and feasibility of its SkinGun and CellMist Systems. The RenovaCare SkinGun and CellMist Systems are used in the CELLMIST 1 clinical trial to topically give autologous skin cells to deep second-degree thermal burn wounds in adults to aid recovery.
